5/15/2007

Mark Thornton, a former medical officer in the FDA Office of Oncology Products, criticized the agency for failing to approve two "safe, promising" therapies designed to stimulate a patient's immune system to fight cancer. "While our lawmakers obsess over FDA 'safety reforms,' no one is holding this government agency accountable for its complicity in stalling therapies for life-threatening diseases," Thornton said.

Related Summaries